{
    "xml": "<topic id=\"PHP2261\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/zuclopenthixol\" basename=\"zuclopenthixol\" title=\"ZUCLOPENTHIXOL\">\n<title>ZUCLOPENTHIXOL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_390\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/zuclopenthixol\">Zuclopenthixol</xref>\n</p>\n<data name=\"vtmid\">429346008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP42409\" outputclass=\"indicationsAndDose\" rev=\"1.40\" parent=\"/drugs/zuclopenthixol\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia and other psychoses</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 20&#8211;30&#8239;mg daily in divided doses, increased if necessary up to 150&#8239;mg daily; usual maintenance 20&#8211;50&#8239;mg daily (max. per dose 40&#8239;mg), for debilitated patients, use elderly dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 5&#8211;15&#8239;mg daily in divided doses, increased if necessary up to 150&#8239;mg daily; usual maintenance 20&#8211;50&#8239;mg daily (max. per dose 40&#8239;mg).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42465\" outputclass=\"contraindications\" rev=\"1.16\" parent=\"/drugs/zuclopenthixol\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Apathetic states</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>; <ph outputclass=\"contraindication\">withdrawn states</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42486\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/zuclopenthixol\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP42341\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/zuclopenthixol\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Urinary frequency</ph>; <ph outputclass=\"sideEffect\">urinary incontinence</ph>; <ph outputclass=\"sideEffect\">weight loss (less common than weight gain)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42380\" outputclass=\"pregnancy\" parent=\"/drugs/zuclopenthixol\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42500\" outputclass=\"breastFeeding\" parent=\"/drugs/zuclopenthixol\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42426\" outputclass=\"hepaticImpairment\" parent=\"/drugs/zuclopenthixol\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Halve dose.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Consider serum-level monitoring in patients with hepatic impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42367\" outputclass=\"renalImpairment\" parent=\"/drugs/zuclopenthixol\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Halve dose in renal failure; smaller starting doses used in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2261-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/zuclopenthixol\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74713\" title=\"Tablet\" namespace=\"/drugs/zuclopenthixol/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"2\" rel=\"backlink\">Psychoses and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_390\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/zuclopenthixol\" title=\"Zuclopenthixol\" count=\"1\" rel=\"link\">Zuclopenthixol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74713\" namespace=\"/drugs/zuclopenthixol/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP2261",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/zuclopenthixol",
    "basename": "zuclopenthixol",
    "title": "ZUCLOPENTHIXOL",
    "interactants": [
        {
            "id": "bnf_int_390",
            "label": "Zuclopenthixol"
        }
    ],
    "vtmid": "429346008",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia and other psychoses",
                        "html": "Schizophrenia and other psychoses"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 20&#8211;30 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20&#8211;50 mg daily (max. per dose 40 mg), for debilitated patients, use elderly dose.",
                        "html": "<p>Initially 20&#8211;30&#8239;mg daily in divided doses, increased if necessary up to 150&#8239;mg daily; usual maintenance 20&#8211;50&#8239;mg daily (max. per dose 40&#8239;mg), for debilitated patients, use elderly dose.</p>"
                    },
                    {
                        "textContent": "Initially 5&#8211;15 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20&#8211;50 mg daily (max. per dose 40 mg).",
                        "html": "<p>Initially 5&#8211;15&#8239;mg daily in divided doses, increased if necessary up to 150&#8239;mg daily; usual maintenance 20&#8211;50&#8239;mg daily (max. per dose 40&#8239;mg).</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Apathetic states",
                "html": "Apathetic states"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            },
            {
                "type": "contraindications",
                "textContent": "withdrawn states",
                "html": "withdrawn states"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Urinary frequency",
                        "html": "Urinary frequency",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urinary incontinence",
                        "html": "urinary incontinence",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "weight loss (less common than weight gain)",
                        "html": "weight loss (less common than weight gain)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Halve dose.",
                "html": "<p>Halve dose.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.",
                "html": "<p>Can precipitate coma.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Consider serum-level monitoring in patients with hepatic impairment.",
                "html": "<p>Consider serum-level monitoring in patients with hepatic impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Halve dose in renal failure; smaller starting doses used in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Halve dose in renal failure; smaller starting doses used in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74713",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_390",
                "label": "Zuclopenthixol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74713",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}